Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...